Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate

MT Newswires Live05-19

Amplia Therapeutics (ASX:ATX) is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.

Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.

The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636071300?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 07:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636071300","market":"sh","top_or_hot":-1,"title":"Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.</p><p>Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.</p><p>The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 07:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.</p><p>Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.</p><p>The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636071300","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636071300","pubTimestamp":1779148606,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4139":"生物科技","BK7067":"生物科技","LENZ":"Therapeutics"},"translate_title":"Amplia Therapeutics将启动胰腺癌候选药物的2B期研究","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636071300","isCrawlerRequest":true}